Research Studies
Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For over 45 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting-edge therapy. At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.
Choosing to participate in a study is an important personal decision. Are you interested in participating in a study? Talk with your doctor and family members or friends about deciding to join a study.
Protocol Name: A Prospective, Multi-Center Clinical Study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis (BARD)
Indication: Patients requiring dialysis, needing creation of AV fistula
PI: Dr. Neghae Mawla, MD
Location: 4401 Tradition Trail Plano, Texas 75093
Protocol Name: Placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of gfb-887, a trpc5 channel inhibitor, in patients with focal segmental glomerulosclerosis, and treatment-resistant minimal change disease (Goldfinch)
Indication: Patients with FSGS & treatment resistant minimal change in disease
PI: Dr. Venkata Yalamanchilli
Location: 2651 Bolton Boone Drive, Desoto, TX 75115
Protocol Name: FLEX AV device study Vessel Prep Prior to the Treatment of Obstructive Lesions in the Native Arteriovenous Dialysis Fistula (AVF)
Indication: Obstructive Lesions in the Native Arteriovenous Dialysis Fistula (AVF)
Primary Investigator:
Dr. Neghae Mawla
Location:
Plano Vascular office – 4401 Tradition Trail Plano, TX 75093
Protocol Name: Novo-Nordisk ZEUS Study- Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Indication: Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Primary Investigator:
Dr. Ankit Mehta
Location:
1420 Viceroy Drive, Dallas, TX 75235
Protocol Name: Prospective, Randomized, Controlled, Multicenter Study Comparing the Merit WRAPSODYTM Endovascular Stent Graft to Percutaneous Transluminal Angioplasty for Treatment of Venous Outflow Circuit Stenosis or Occlusion in Hemodialysis Patients ( Merit Wave Study)(Plano)
Indication: Treatment of Venous Outflow Circuit Stenosis or Occlusion in Hemodialysis Patients
Primary Investigators:
Dr. Neghae Mawla, MD (Plano)
Dr. Jeffrey Siegel, MD (Dallas)
Locations:
Plano Vascular-4401 Tradition Trail Plano, Texas 75093
Dallas Vascular – 3604 Live Oak St. Suite 300, Dallas, Texas, 75204
Protocol Name: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
Indication: Proteinuric
Primary Investigator: Dr. Akinwande Akinfolarin
Location: Landry office – 411 N. Washington Ave Suite 7000, Dallas, TX 75246
Protocol Name: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
Indication: Patients with IgA Nephropathy at Risk of Progressive loss of renal function
Primary Investigator: Dr. Akinwande Akinfolarin
Location: Landry office – 411 N. Washington Ave Suite 7000, Dallas, TX 75246
Protocol Name: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection (LionHeart21)(New)
Primary Investigator: Dr. Arthi Rajagopal
Indication: Treatment of CMV Infection in Kidney Transplant Recipients
Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 7523
Protocol Name: A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium On Serum Potassium and Serum Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease (NEUTRALIZE)(New)
Primary Investigator: Dr. Shahbaz Ahmed
Indication: Patients with hyperkalemia and metabolic acidosis associated with CKD
Location: Landry Office – 411 N. WASHINGTON AVENUE SUITE 7000 DALLAS, TX 75246
Protocol Name: Expanded Access Treatment with Open-Label Pegunigalsidase Alfa for Fabry Patients (Fabry)(New)
Primary Investigator: Dr. Ankit Mehta
Indication: Treatment for Patients with Fabry Disease
Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235
Protocol Name: A repeat dose, open-label, two-period, randomized, cross over study to compare the effect of daprodustat to recombinant, human erythropoietin on oral iron absorption in adult participants with anemia associated with chronic kidney disease who are not on dialysis”
Indication: Patients with Anemia Associated with Chronic Kidney Disease
PI: Dr. Bernard Fischbach
Location: Fort Worth office -1250 Eighth Ave, Suite 135 Fort Worth, TX 76104
Protocol Name: A phase 3 trial of the efficacy and safety of bardoxolone methyl in patients with autosomal dominant polycystic kidney disease. (Falcon)
Indication: Autosomal dominant polycystic kidney disease – PKD
PI: Dr. Ankit Mehta
Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235
Protocol Name: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IGAN). (Omeros)
Indication: Immunoglobin nephropathy – IgA
PI: Dr. Akinwande Akinfolarin
Location: Landry Office – 411 N. WASHINGTON AVENUE SUITE 7000 DALLAS, TX 75246
Protocol Name: Clinical study protocol a pivotal phase 3 trial to evaluate the safety and efficacy of clazakizumab for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients (Imagine)
Indication: Chronic active antibody-mediated rejection in kidney transplant recipients
PI: Dr. Bernard Fischbach
Location: Corporate office – 1420 VICEROY DRIVE DALLAS, TX 75235
Protocol Name: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients (Amplyx)
PI: Dr. Bernard Fischbach
Indication: Treatment of BK Viremia in Kidney Transplant Recipients
Location: Corporate office – 1420 VICEROY DRIVE DALLAS, TX 75235
Protocol Name: Establishing the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-blind, Placebo-Controlled Study. (Allena 302)
PI: Dr. Michael Wiederkher
Indication: Patients with Enteric Hyperoxaluria
Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235